Caplyta Reduces Acute Bipolar Mania in Phase 3

Company Johnson and Johnson Event Type Phase 3 Clinical Readout Modality Oral Atypical Antipsychotic (Small Molecule) Asset Caplyta (Lumateperone) Target Serotonin 5-HT2A Antagonism and Dopamine D2 Partial Agonism (Proposed) Disease Area Bipolar I Disorder, Acute Mania Summary Johnson and Johnson reported that once-daily lumateperone 42…